Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-11
2010-06-01
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S300100, C548S302700, C548S304400, C548S309700, C514S385000
Reexamination Certificate
active
07728026
ABSTRACT:
Compounds of Formula (I)inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), method of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compound of Formula (I).
REFERENCES:
patent: 3864385 (1975-02-01), Felt et
patent: 4093726 (1978-06-01), Winn et al.
patent: 6372736 (2002-04-01), Kemp et al.
patent: 6448271 (2002-09-01), Lubisch et al.
patent: 6509365 (2003-01-01), Lubisch et al.
patent: 6696437 (2004-02-01), Lubisch et al.
patent: 6737421 (2004-05-01), Lubish et al.
patent: RE39608 (2007-05-01), Lubisch et
patent: 7462724 (2008-12-01), Penning et al.
patent: 7550603 (2009-06-01), Zhu et al.
patent: 2003/0100582 (2003-05-01), Sircar et al.
patent: 2006/0229289 (2006-10-01), Zhu et al.
patent: 2007/0179136 (2007-08-01), Penning et al.
patent: 2007/0259937 (2007-11-01), Giranda et al.
patent: 2007/0265324 (2007-11-01), Wernet et al.
patent: 2009/0030016 (2009-01-01), Ghandhi et al.
patent: 3522230 (1987-01-01), None
patent: 3830060 (1990-03-01), None
patent: 19916460 (2000-10-01), None
patent: 10021468 (2001-11-01), None
patent: 19920936 (2001-11-01), None
patent: 1354554 (1974-06-01), None
patent: 2002-141067 (2002-05-01), None
patent: 97/04771 (1997-02-01), None
patent: 98/39343 (1998-09-01), None
patent: 00/29384 (2000-05-01), None
patent: 00/32579 (2000-06-01), None
patent: 00/64878 (2000-11-01), None
patent: 01/21615 (2001-03-01), None
patent: 01/21634 (2001-03-01), None
patent: 01/82877 (2001-11-01), None
patent: 02/68407 (2002-06-01), None
patent: 03/020698 (2003-03-01), None
patent: 03/094861 (2003-11-01), None
patent: WO 03/106430 (2003-12-01), None
patent: 2004/054515 (2004-07-01), None
patent: 2004/065370 (2004-08-01), None
patent: 2004/096793 (2004-11-01), None
patent: 2004/098494 (2004-11-01), None
patent: 00/26192 (2005-05-01), None
patent: WO 2005/044988 (2005-05-01), None
patent: WO 2006/023400 (2006-02-01), None
Skalitzky et al (2003): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2003:1006960.
PCT Search Report from PCT/US2006/013366 mailed on Aug. 18, 2006.
Alexy, et al., “Inhibition ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors”, Journal Cardiovascular of Pharmacol 43(3), 423-431 (2004).
Burkart, V., “Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destructin and diabetes development induced by streptozocin”, Nat. Med., 5(3):314-319 (1999).
Chen, et al., “Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide”, Cancer Chem. Pharm., 22:303-307 (1966).
Cuzzocrea, “Protective effects of 3-aminobenzamide, an Inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation”, Eur. J. of Pharm., 342:67-76 (1998).
Ehrlich, W., et al., “Inhibition of the induction of collagenase by interleukin-1 in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide”, Rheumatol Int., 15:171-172 (1995).
Gilchrist, et al., “Cyclisation of ortho-Substituted N-Arylben zimidoyl Nitrenes. Part 2. Preferential Cyclisatlons at an ortho-Position Bearin a Methoxycarbonyl Group”, Journal of Chem. Society, Perkin Transactions 1, GB, Chemical Society, Letchworth, 2303-2307 (1979).
Griffin, et al., “Resistance modifying agents 3. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase,” Pharmaceutical Sciences, 2(1), 43-47 (1996).
Kröger, H., “Synergistic Effects of Thalidomide and Poly(ADP-Ribose) Polymerase Inhibition of Type II Collagen-Induced Arthritis in Mice”, Inflammation, 20(2):203-215 (1996).
Poste, et al., “Methods in Cell Biology,” Academic Press, Inc., vol. XIV, pp. 33-71, 1976.
Szabo, C., et al., “Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase”, Proc. Natl., Acad. Sci. USA, 95:38673872 (1998).
Thiemermann, C., et al., “Inhibition of the activity of poly (ADP ribose) synthhetase reduces ischemia-reperfusion injury in the heart and skeletal muscle”, Proc. Natl. Acad. Sci. USA, 94:679-683 (1997).
Welkin, D., et al., “Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly(ADP-Ribose)Polymerase Inhibitor”, Int. J. Immunopharmac., 17(4)265-271 (1995).
White, et al., “Potentiation of cytotoxic drug activity in human tumore cell lines, by amine-substituted 2-arylbenzimioazol-4carboxamide PARP-1 inhibitors”, Bioorganic & Medicinal Chemistry Letters, 14(10), 2433-2437 (2004).
Co-pending U.S. Appl. No. 09/830,992.
Co-pending U.S. Appl. No. 11/536,994.
Co-pending U.S. Appl. No. 11/623,996.
Co-pending U.S. Appl. No. 11/830,318.
Co-pending U.S. Appl. No. 11/970,828.
Co-pending U.S. Appl. No. 12/058,478.
Co-pending U.S. Appl. No. 12/116,823.
Co-pending U.S. Appl. No. 12/117,452.
Co-pending U.S. Appl. No. 12/173,213.
Co-pending U.S. Appl. No. 12/413,834.
Gandhi Virajkumar B.
Giranda Vincent L.
Gong Jianchun
Penning Thomas D.
Thomas Sheela
Abbott Laboratories Inc.
Shameem Golam M
Steele Susan L.
LandOfFree
2-substituted-1 h-benzimidazile-4-carboxamides are PARP... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-substituted-1 h-benzimidazile-4-carboxamides are PARP..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-substituted-1 h-benzimidazile-4-carboxamides are PARP... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4206794